Formulation Development
Lonza joins GENEGUT Project to Develop a Capsule Delivery Solution for an Innovative Crohn's Disease Treatment
Lonza recently announced its participation in the GENEGUT project to develop an innovative functional capsule-based delivery solution for therapies targeting….
Lonza Expands Global Process Development Team & Laboratory Spaces for Cell & Gene Development
Lonza recently announced it is expanding its cell and gene therapies (CGT) process and analytical development laboratories at its locations in Houston, TX, and Geleen…
Acumen’s Anti-Amyloid Beta Oligomer Antibody Granted FDA Fast Track Designation for Alzheimer's Disease
Acumen Pharmaceuticals, Inc. recently announced ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs), has been granted Fast Track designation for the treatment of early Alzheimer’s disease by….
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease
Phathom Pharmaceuticals, Inc. recently announced it has completed enrollment in its PHALCON-NERD Daily Dosing Phase 3 trial of vonoprazan in non-erosive gastroesophageal reflux disease (NERD).…
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections From Ongoing Phase 3 Study
SCYNEXIS, Inc. recently announced the presentation of cumulative interim outcomes and all-cause mortality data in patients with refractory candidiasis treated with oral ibrexafungerp from the…
Catalent Expands Biologics Analytical Capabilities With New Laboratories at Center of Excellence in Kansas City, MO
Catalent recently announced a $12-million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, MO. The project will see…
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
Comera Life Sciences Holdings, Inc. recently announced favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study, the preclinical results showed that Comera’s…
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating Treatment of B-cell Acute Lymphoblastic Leukemia
Gracell Biotechnologies Inc. recently announced the first patient has been dosed in the Phase 2 portion of its registrational Phase 1/2 clinical trial evaluating GC007g…
Bora Pharmaceutical Makes Strategic Appointment to Strengthen Global Manufacturing Capabilities
Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO), recently appointed Don Liscombe as its Vice President and General Manager to lead its flagship…
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
PTC Therapeutics, Inc. recently announced enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington's disease at…
Alvotech & JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates, Bringing New Options for Patients in Specialty Care
Alvotech and the JAMP Pharma Group recently announced the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding…
Jazz Pharmaceuticals & Zymeworks Announce Exclusive License Agreement
Jazz Pharmaceuticals plc and Zymeworks Inc. recently announced Jazz and Zymeworks’ subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire….
Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
Societal CDMO, Inc. recently announced it has signed CDMO service agreements with two new customers. These contracts are focused on a range of analytical method, technical transfer, formulation, manufacturing and….
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Preclinical Study
Silo Pharma, Inc. recently announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD), as demonstrated in a mouse…
Aragen to Operationalize Cutting-Edge Formulation Manufacturing Facility
Aragen recently announced it will operationalize its state-of-the-art formulation manufacturing facility in the Mallapur campus, Hyderabad, India, by January 2023. The 12,000-sq-ft new facility will…
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Crinetics Pharmaceuticals, Inc. recently announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating…
VBI Vaccines & Agenus Announce Collaboration to Evaluate VBI-1901 in Combination With Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
VBI Vaccines Inc. and Agenus recently announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal….
Tavros Therapeutics & Vividion Therapeutics Announce Strategic Collaboration to Discover & Enhance Targeted Oncology Programs
Tavros Therapeutics and Vividion Therapeutics, Inc. recently announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term…..
BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. recently announced today it has added Mayo Clinic, Jacksonville, FL, as a clinical site in the Phase 1/2 study of BriaCell’s lead…
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients With Krabbe Disease
Forge Biologics recently announced Chief Medical Officer Maria Escolar, MD, MS, presented updated clinical data from the RESKUE Phase 1/2 clinical trial for FBX-101—the company’s…
